Aveo
February 15, 2012
Text size
–
+
Aveo Pharmaceuticals Inc. reported a wider fourth-quarter loss Tuesday as it continued to study its experimental cancer drugs tivozanib and ficlatuzumab. Aveo said it lost $25.2 million, or 58 cents per share, during the fourth quarter. A year earlier it posted a loss of $10.3 million, or 30 cents per share. Revenue from collaborations with companies like Astellas Pharma and Johnson & Johnson fell to $1.1 million from $12 million. Analysts expected the company to report a loss of 57 cents per share and $5 million in revenue, according to FactSet.
For more from BostonGlobe.com, sign up or log in below
To continue, please sign up or log in to BostonGlobe.com
Access the full articles and quality reporting of The Boston Globe at BostonGlobe.com
Sign up
Unlimited Access to BostonGlobe.com for 4 weeks for only 99¢.
Are you a Boston Globe home delivery subscriber?
Get FREE access as part of your print subscription.
BostonGlobe.com subscriber
Click to continue reading this article or to log in to BostonGlobe.com.
